Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream

This study has been withdrawn prior to enrollment.
(Study withdrawn due to volunteer disinterest in participating.)
Sponsor:
Information provided by (Responsible Party):
Anna Chien, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT01349556
First received: May 5, 2011
Last updated: April 21, 2014
Last verified: April 2014

May 5, 2011
April 21, 2014
May 2011
March 2014   (final data collection date for primary outcome measure)
EGFRi rash severity [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01349556 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream
Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin

This research is being done to study whether using of topical tretinoin can help prevent the common rash that patients often get while taking epidermal growth factor inhibitor (EGFR-I) medications such ascetuximab or erlotinib.

Patients taking EGFR-I medications often develop skin irritation and acne-like bumps on their face, chest, and other areas. This rash from EGFR-I's is often treated with moisturizers and topical or oral antibiotics. However, there has not yet been a study looking at a way to prevent this common side effect from occurring, and topical tretinoin may be useful in reducing the rash.

Tretinoin 0.025% cream is approved by the Food and Drug Administration (FDA) for the treatment of acne, acne scarring, and photodamage. It is not approved for use in preventing rashes associated with EGFR-I's.

Not Provided
Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Medication Reaction
Drug: Tretinoin
tretinoin 0.025% cream
Experimental: Tretinoin pre-treatment
Intervention: Drug: Tretinoin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
March 2014
March 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18 years or over
  • Scheduled to begin treatment with an EGFR inhibitor drug

Exclusion Criteria:

  • Pregnant or nursing
  • History of bleeding disorder
  • History of keloids or large, thick, puffy-looking scars in the last 10 years
  • Used topical retinoids in the last year (e.g. tretinoin/Retin-A, adapalene/Differin, tazarotene/Tazorac)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01349556
NA_00042104
Not Provided
Anna Chien, Johns Hopkins University
Johns Hopkins University
Not Provided
Principal Investigator: Anna L Chien, MD Johns Hopkins Dermatology
Johns Hopkins University
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP